Global Sex Hormone Antagonist 麻豆原创 Research Report 2023

Publication ID:

PB511234383

Publication Date:

November 2, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

A sex hormone antagonist is a drug that blocks the effects of sex hormones, such as testosterone, estrogen, and progesterone. Sex hormones play a role in many bodily functions, including sexual development, reproduction, and metabolism.
The global Sex Hormone Antagonist market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029.
The growth of the market is attributed to the increasing prevalence of hormone-related diseases, rising demand for effective treatments for hormone-related diseases, and growing awareness of the benefits of sex hormone antagonist therapy.
Here are some of the factors driving the growth of the sex hormone antagonist market:
Increasing prevalence of hormone-related diseases: Hormone-related diseases such as prostate cancer, breast cancer, and endometrial cancer are becoming more common. This is due to a number of factors, including aging population, changing lifestyles, and environmental factors.
Rising demand for effective treatments for hormone-related diseases: As the prevalence of hormone-related diseases increases, so does the demand for effective treatments. Sex hormone antagonists are an important class of drugs that can be used to treat a variety of hormone-related diseases.
Growing awareness of the benefits of sex hormone antagonist therapy: The awareness of the benefits of sex hormone antagonist therapy is growing among both patients and healthcare professionals. This is leading to increased demand for sex hormone antagonist drugs.
The sex hormone antagonist market is expected to continue to grow in the coming years, driven by the factors mentioned above.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Sex Hormone Antagonist market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Merck
Sanofi
Eli Lilly and Company
Kyowa Kirin International
Bayer
Orion Corporation
Hengrui
Schering-Plough
Hinova Pharma
Jiangsu Hengrui Pharmaceuticals
Segment by Type
Antiestrogen
Antiprogestin
Antiandrogen
Segment by Application
Breast Cancer
Prostate Cancer
Endometriosis
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Sex Hormone Antagonist report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Sex Hormone Antagonist 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Antiestrogen
1.2.3 Antiprogestin
1.2.4 Antiandrogen
1.3 麻豆原创 by Application
1.3.1 Global Sex Hormone Antagonist 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Breast Cancer
1.3.3 Prostate Cancer
1.3.4 Endometriosis
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Sex Hormone Antagonist 麻豆原创 Perspective (2018-2029)
2.2 Sex Hormone Antagonist Growth Trends by Region
2.2.1 Global Sex Hormone Antagonist 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Sex Hormone Antagonist Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Sex Hormone Antagonist Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Sex Hormone Antagonist 麻豆原创 Dynamics
2.3.1 Sex Hormone Antagonist Industry Trends
2.3.2 Sex Hormone Antagonist 麻豆原创 Drivers
2.3.3 Sex Hormone Antagonist 麻豆原创 Challenges
2.3.4 Sex Hormone Antagonist 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Sex Hormone Antagonist Players by Revenue
3.1.1 Global Top Sex Hormone Antagonist Players by Revenue (2018-2023)
3.1.2 Global Sex Hormone Antagonist Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Sex Hormone Antagonist 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Sex Hormone Antagonist Revenue
3.4 Global Sex Hormone Antagonist 麻豆原创 Concentration Ratio
3.4.1 Global Sex Hormone Antagonist 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Sex Hormone Antagonist Revenue in 2022
3.5 Sex Hormone Antagonist Key Players Head office and Area Served
3.6 Key Players Sex Hormone Antagonist Product Solution and Service
3.7 Date of Enter into Sex Hormone Antagonist 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Sex Hormone Antagonist Breakdown Data by Type
4.1 Global Sex Hormone Antagonist Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Sex Hormone Antagonist Forecasted 麻豆原创 Size by Type (2024-2029)
5 Sex Hormone Antagonist Breakdown Data by Application
5.1 Global Sex Hormone Antagonist Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Sex Hormone Antagonist Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Sex Hormone Antagonist 麻豆原创 Size (2018-2029)
6.2 North America Sex Hormone Antagonist 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Sex Hormone Antagonist 麻豆原创 Size by Country (2018-2023)
6.4 North America Sex Hormone Antagonist 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Sex Hormone Antagonist 麻豆原创 Size (2018-2029)
7.2 Europe Sex Hormone Antagonist 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Sex Hormone Antagonist 麻豆原创 Size by Country (2018-2023)
7.4 Europe Sex Hormone Antagonist 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Sex Hormone Antagonist 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Sex Hormone Antagonist 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Sex Hormone Antagonist 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Sex Hormone Antagonist 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Sex Hormone Antagonist 麻豆原创 Size (2018-2029)
9.2 Latin America Sex Hormone Antagonist 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Sex Hormone Antagonist 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Sex Hormone Antagonist 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Sex Hormone Antagonist 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Sex Hormone Antagonist 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Sex Hormone Antagonist 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Sex Hormone Antagonist 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Sex Hormone Antagonist Introduction
11.1.4 Pfizer Revenue in Sex Hormone Antagonist Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Detail
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Sex Hormone Antagonist Introduction
11.2.4 Johnson & Johnson Revenue in Sex Hormone Antagonist Business (2018-2023)
11.2.5 Johnson & Johnson Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Detail
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Sex Hormone Antagonist Introduction
11.3.4 AstraZeneca Revenue in Sex Hormone Antagonist Business (2018-2023)
11.3.5 AstraZeneca Recent Development
11.4 Astellas
11.4.1 Astellas Company Detail
11.4.2 Astellas Business Overview
11.4.3 Astellas Sex Hormone Antagonist Introduction
11.4.4 Astellas Revenue in Sex Hormone Antagonist Business (2018-2023)
11.4.5 Astellas Recent Development
11.5 Merck
11.5.1 Merck Company Detail
11.5.2 Merck Business Overview
11.5.3 Merck Sex Hormone Antagonist Introduction
11.5.4 Merck Revenue in Sex Hormone Antagonist Business (2018-2023)
11.5.5 Merck Recent Development
11.6 Sanofi
11.6.1 Sanofi Company Detail
11.6.2 Sanofi Business Overview
11.6.3 Sanofi Sex Hormone Antagonist Introduction
11.6.4 Sanofi Revenue in Sex Hormone Antagonist Business (2018-2023)
11.6.5 Sanofi Recent Development
11.7 Eli Lilly and Company
11.7.1 Eli Lilly and Company Company Detail
11.7.2 Eli Lilly and Company Business Overview
11.7.3 Eli Lilly and Company Sex Hormone Antagonist Introduction
11.7.4 Eli Lilly and Company Revenue in Sex Hormone Antagonist Business (2018-2023)
11.7.5 Eli Lilly and Company Recent Development
11.8 Kyowa Kirin International
11.8.1 Kyowa Kirin International Company Detail
11.8.2 Kyowa Kirin International Business Overview
11.8.3 Kyowa Kirin International Sex Hormone Antagonist Introduction
11.8.4 Kyowa Kirin International Revenue in Sex Hormone Antagonist Business (2018-2023)
11.8.5 Kyowa Kirin International Recent Development
11.9 Bayer
11.9.1 Bayer Company Detail
11.9.2 Bayer Business Overview
11.9.3 Bayer Sex Hormone Antagonist Introduction
11.9.4 Bayer Revenue in Sex Hormone Antagonist Business (2018-2023)
11.9.5 Bayer Recent Development
11.10 Orion Corporation
11.10.1 Orion Corporation Company Detail
11.10.2 Orion Corporation Business Overview
11.10.3 Orion Corporation Sex Hormone Antagonist Introduction
11.10.4 Orion Corporation Revenue in Sex Hormone Antagonist Business (2018-2023)
11.10.5 Orion Corporation Recent Development
11.11 Hengrui
11.11.1 Hengrui Company Detail
11.11.2 Hengrui Business Overview
11.11.3 Hengrui Sex Hormone Antagonist Introduction
11.11.4 Hengrui Revenue in Sex Hormone Antagonist Business (2018-2023)
11.11.5 Hengrui Recent Development
11.12 Schering-Plough
11.12.1 Schering-Plough Company Detail
11.12.2 Schering-Plough Business Overview
11.12.3 Schering-Plough Sex Hormone Antagonist Introduction
11.12.4 Schering-Plough Revenue in Sex Hormone Antagonist Business (2018-2023)
11.12.5 Schering-Plough Recent Development
11.13 Hinova Pharma
11.13.1 Hinova Pharma Company Detail
11.13.2 Hinova Pharma Business Overview
11.13.3 Hinova Pharma Sex Hormone Antagonist Introduction
11.13.4 Hinova Pharma Revenue in Sex Hormone Antagonist Business (2018-2023)
11.13.5 Hinova Pharma Recent Development
11.14 Jiangsu Hengrui Pharmaceuticals
11.14.1 Jiangsu Hengrui Pharmaceuticals Company Detail
11.14.2 Jiangsu Hengrui Pharmaceuticals Business Overview
11.14.3 Jiangsu Hengrui Pharmaceuticals Sex Hormone Antagonist Introduction
11.14.4 Jiangsu Hengrui Pharmaceuticals Revenue in Sex Hormone Antagonist Business (2018-2023)
11.14.5 Jiangsu Hengrui Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Merck
Sanofi
Eli Lilly and Company
Kyowa Kirin International
Bayer
Orion Corporation
Hengrui
Schering-Plough
Hinova Pharma
Jiangsu Hengrui Pharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.